Lantern Pharma to Host Q3 2025 Results Webcast, Highlighting AI-Driven Oncology Pipeline
Lantern Pharma will review its third-quarter 2025 financial results and AI platform developments during a November webcast, showcasing how artificial intelligence is accelerating cancer drug discovery and development.
Lantern Pharma Inc. (NASDAQ: LTRN) announced it will host a webcast on November 13, 2025, to review third-quarter operating and financial results and provide updates on its artificial intelligence platform development. The event, scheduled for 9 a.m. Eastern Time, will feature President and CEO Panna Sharma alongside other management team members discussing quarterly performance, clinical trial progress, and upcoming milestones for the company's AI and machine learning initiatives.
The significance of this announcement lies in demonstrating how AI-driven approaches are transforming oncology drug development. Lantern Pharma's proprietary RADR platform leverages over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms to address what the company describes as billion-dollar problems in cancer drug development. This approach represents a fundamental shift in how pharmaceutical companies approach drug discovery, potentially reducing both costs and development timelines significantly.
Lantern Pharma's growing pipeline spans multiple cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company currently has a Phase 2 clinical program and multiple Phase 1 clinical trials underway. The full details of the upcoming webcast and corporate developments can be found in the company's official press release available at https://ibn.fm/BMDrb.
The broader implications of Lantern Pharma's AI-driven approach extend beyond the company itself to the entire pharmaceutical industry. By harnessing artificial intelligence to accelerate drug discovery and development, the company aims to address what has traditionally been one of the most time-consuming and expensive aspects of pharmaceutical research. The company estimates its pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion, potentially providing life-changing therapies to hundreds of thousands of cancer patients worldwide.
Investors and industry observers can access the latest news and updates relating to Lantern Pharma through the company's dedicated newsroom at https://ibn.fm/LTRN. The upcoming webcast will provide crucial insights into how AI technology is being practically applied to solve real-world challenges in oncology drug development, offering a window into the future of pharmaceutical research methodology.